Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation.

International journal of immunogenetics

Norden J, Pearce KF, Irving JAE, Collin MP, Wang XN, Wolff D, Kolb HJ, Socie G, Kuzmina Z, Greinix H, Holler E, Rocha V, Gluckman E, Hromadnikova I, Dickinson AM.
PMID: 30043490
Int J Immunogenet. 2018 Jul 25; doi: 10.1111/iji.12380. Epub 2018 Jul 25.

Haematopoietic stem cell transplantation (HSCT) remains the only cure for most haematological malignancies, however, the mortality rate remains high. Complications after HSCT include relapse, graft versus host disease (GvHD), graft rejection and infection. Over the last few years several...

Cite
Norden J, Pearce KF, Irving JAE, et al. The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation. Int J Immunogenet. 2018;doi: 10.1111/iji.12380.
Norden, J., Pearce, K. F., Irving, J. A. E., Collin, M. P., Wang, X. N., Wolff, D., Kolb, H. J., Socie, G., Kuzmina, Z., Greinix, H., Holler, E., Rocha, V., Gluckman, E., Hromadnikova, I., & Dickinson, A. M. (2018). The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation. International journal of immunogenetics, . https://doi.org/10.1111/iji.12380
Norden, Jean, et al. "The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation." International journal of immunogenetics vol. (2018). doi: https://doi.org/10.1111/iji.12380
Norden J, Pearce KF, Irving JAE, Collin MP, Wang XN, Wolff D, Kolb HJ, Socie G, Kuzmina Z, Greinix H, Holler E, Rocha V, Gluckman E, Hromadnikova I, Dickinson AM. The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation. Int J Immunogenet. 2018 Jul 25; doi: 10.1111/iji.12380. Epub 2018 Jul 25. PMID: 30043490.
Copy Download .nbib Format: NLM
Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Helmberg W, Sipurzynski S, Groselje-Strehle A, Greinix H, Schlenke P.
PMID: 32595424
Transfus Med Hemother. 2020 Jun;47(3):198-204. doi: 10.1159/000506750. Epub 2020 Mar 27.

BACKGROUND: Extracorporeal photopheresis is a therapy based on the induction of apoptosis to cells harvested from peripheral blood, followed by direct retransfusion. Currently, there are two approaches: inline procedures, where cell harvesting, 8-methoxypsoralen (8-MOP) incubation, and UV irradiation is...

Cite
Helmberg W, Sipurzynski S, Groselje-Strehle A, et al. Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis. Transfus Med Hemother. 2020;47(3):198-204doi: 10.1159/000506750.
Helmberg, W., Sipurzynski, S., Groselje-Strehle, A., Greinix, H., & Schlenke, P. (2020). Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 47(3), 198-204. https://doi.org/10.1159/000506750
Helmberg, Wolfgang, et al. "Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 47,3 (2020): 198-204. doi: https://doi.org/10.1159/000506750
Helmberg W, Sipurzynski S, Groselje-Strehle A, Greinix H, Schlenke P. Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis. Transfus Med Hemother. 2020 Jun;47(3):198-204. doi: 10.1159/000506750. Epub 2020 Mar 27. PMID: 32595424; PMCID: PMC7315144.
Copy Download .nbib Format: NLM
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.

Haematologica

Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, Chabannon C, Styczynski J, Nagler A, Robin M, Robinson S, Chalandon Y, Mikulska M, Schönland S, Peric Z, Ruggeri A, Lanza F, De Wreede LC, Mohty M, Basak GW, Kröger N.
PMID: 34162176
Haematologica. 2021 Jun 24; doi: 10.3324/haematol.2020.265769. Epub 2021 Jun 24.

Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome after allogeneic hematopoietic cell transplantation. Advances in prophylaxis and supportive care have taken place over the years. The aim of this study is to test whether incidence and...

Cite
Greinix HT, Eikema DJ, Koster L, et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica. 2021;doi: 10.3324/haematol.2020.265769.
Greinix, H. T., Eikema, D. J., Koster, L., Penack, O., Yakoub-Agha, I., Montoto, S., Chabannon, C., Styczynski, J., Nagler, A., Robin, M., Robinson, S., Chalandon, Y., Mikulska, M., Schönland, S., Peric, Z., Ruggeri, A., Lanza, F., De Wreede, L. C., Mohty, M., Basak, G. W., & Kröger, N. (2021). Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica, . https://doi.org/10.3324/haematol.2020.265769
Greinix, Hildegard T, et al. "Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2020.265769
Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, Chabannon C, Styczynski J, Nagler A, Robin M, Robinson S, Chalandon Y, Mikulska M, Schönland S, Peric Z, Ruggeri A, Lanza F, De Wreede LC, Mohty M, Basak GW, Kröger N. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica. 2021 Jun 24; doi: 10.3324/haematol.2020.265769. Epub 2021 Jun 24. PMID: 34162176.
Copy Download .nbib Format: NLM
Metabolomics: a novel way to diagnose cGVHD?.

Blood

Greinix HT.
PMID: 35024812
Blood. 2022 Jan 13;139(2):161-162. doi: 10.1182/blood.2021014041.

No abstract available.

Cite
Greinix HT. Metabolomics: a novel way to diagnose cGVHD?. Blood. 2022;139(2):161-162doi: 10.1182/blood.2021014041.
Greinix, H. T. (2022). Metabolomics: a novel way to diagnose cGVHD?. Blood, 139(2), 161-162. https://doi.org/10.1182/blood.2021014041
Greinix, Hildegard T. "Metabolomics: a novel way to diagnose cGVHD?." Blood vol. 139,2 (2022): 161-162. doi: https://doi.org/10.1182/blood.2021014041
Greinix HT. Metabolomics: a novel way to diagnose cGVHD?. Blood. 2022 Jan 13;139(2):161-162. doi: 10.1182/blood.2021014041. PMID: 35024812.
Copy Download .nbib Format: NLM
Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study.

Therapeutic advances in hematology

Spindelboeck W, Halwachs B, Bayer N, Huber-Krassnitzer B, Schulz E, Uhl B, Gaksch L, Hatzl S, Bachmayr V, Kleissl L, Kump P, Deutsch A, Stary G, Greinix H, Gorkiewicz G, Högenauer C, Neumeister P.
PMID: 34987741
Ther Adv Hematol. 2021 Dec 21;12:20406207211058333. doi: 10.1177/20406207211058333. eCollection 2021.

INTRODUCTION: Treatment-refractory, acute graft-METHODS: Consecutive patients with treatment-refractory GI-GvHD were treated with up to six endoscopically applied FMTs.RESULTS: We observed the response to FMT in four out of nine patients with severe, treatment refractory GI-GvHD, associated with a significant...

Cite
Spindelboeck W, Halwachs B, Bayer N, et al. Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Ther Adv Hematol. 2021;12:20406207211058333doi: 10.1177/20406207211058333.
Spindelboeck, W., Halwachs, B., Bayer, N., Huber-Krassnitzer, B., Schulz, E., Uhl, B., Gaksch, L., Hatzl, S., Bachmayr, V., Kleissl, L., Kump, P., Deutsch, A., Stary, G., Greinix, H., Gorkiewicz, G., Högenauer, C., & Neumeister, P. (2021). Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Therapeutic advances in hematology, 1220406207211058333. https://doi.org/10.1177/20406207211058333
Spindelboeck, Walter, et al. "Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study." Therapeutic advances in hematology vol. 12 (2021): 20406207211058333. doi: https://doi.org/10.1177/20406207211058333
Spindelboeck W, Halwachs B, Bayer N, Huber-Krassnitzer B, Schulz E, Uhl B, Gaksch L, Hatzl S, Bachmayr V, Kleissl L, Kump P, Deutsch A, Stary G, Greinix H, Gorkiewicz G, Högenauer C, Neumeister P. Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Ther Adv Hematol. 2021 Dec 21;12:20406207211058333. doi: 10.1177/20406207211058333. eCollection 2021. PMID: 34987741; PMCID: PMC8721365.
Copy Download .nbib Format: NLM
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.

International journal of molecular sciences

Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ.
PMID: 34948104
Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413311.

The tumor microenvironment (TME) is a critical regulator of tumor growth, progression, and metastasis. Since immune cells represent a large fraction of the TME, they play a key role in mediating pro- and anti-tumor immune responses. Immune escape, which...

Cite
Pansy K, Uhl B, Krstic J, et al. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci. 2021;22(24)doi: 10.3390/ijms222413311.
Pansy, K., Uhl, B., Krstic, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K., Feichtinger, J., & Deutsch, A. J. (2021). Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. International journal of molecular sciences, 22(24), . https://doi.org/10.3390/ijms222413311
Pansy, Katrin, et al. "Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions." International journal of molecular sciences vol. 22,24 (2021). doi: https://doi.org/10.3390/ijms222413311
Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413311. PMID: 34948104; PMCID: PMC8706102.
Copy Download .nbib Format: NLM
Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

Bone marrow transplantation

Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M.
PMID: 31616063
Bone Marrow Transplant. 2020 Apr;55(4):837. doi: 10.1038/s41409-019-0714-y.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Muhsen IN, Hashmi SK, Niederwieser D, et al. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020;55(4):837doi: 10.1038/s41409-019-0714-y.
Muhsen, I. N., Hashmi, S. K., Niederwieser, D., Kroeger, N., Agrawal, S., Pasquini, M. C., Atsuta, Y., Ballen, K. K., Seber, A., Saber, W., Kharfan-Dabaja, M. A., Rasheed, W., Okamoto, S., Khera, N., Wood, W. A., Koh, M. B. C., Greinix, H., Kodera, Y., Szer, J., Horowitz, M. M., Weisdorf, D., & Aljurf, M. (2020). Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone marrow transplantation, 55(4), 837. https://doi.org/10.1038/s41409-019-0714-y
Muhsen, Ibrahim N, et al. "Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries." Bone marrow transplantation vol. 55,4 (2020): 837. doi: https://doi.org/10.1038/s41409-019-0714-y
Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):837. doi: 10.1038/s41409-019-0714-y. PMID: 31616063.
Copy Download .nbib Format: NLM
CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.

Frontiers in immunology

Schulz E, Hodl I, Forstner P, Hatzl S, Sareban N, Moritz M, Fessler J, Dreo B, Uhl B, Url C, Grisold AJ, Khalil M, Kleinhappl B, Enzinger C, Stradner MH, Greinix HT, Schlenke P, Steinmetz I.
PMID: 34950155
Front Immunol. 2021 Dec 07;12:803742. doi: 10.3389/fimmu.2021.803742. eCollection 2021.

Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering from hematologic malignancies or other causes of immunodeficiency...

Cite
Schulz E, Hodl I, Forstner P, et al. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients. Front Immunol. 2021;12:803742doi: 10.3389/fimmu.2021.803742.
Schulz, E., Hodl, I., Forstner, P., Hatzl, S., Sareban, N., Moritz, M., Fessler, J., Dreo, B., Uhl, B., Url, C., Grisold, A. J., Khalil, M., Kleinhappl, B., Enzinger, C., Stradner, M. H., Greinix, H. T., Schlenke, P., & Steinmetz, I. (2021). CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients. Frontiers in immunology, 12803742. https://doi.org/10.3389/fimmu.2021.803742
Schulz, Eduard, et al. "CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients." Frontiers in immunology vol. 12 (2021): 803742. doi: https://doi.org/10.3389/fimmu.2021.803742
Schulz E, Hodl I, Forstner P, Hatzl S, Sareban N, Moritz M, Fessler J, Dreo B, Uhl B, Url C, Grisold AJ, Khalil M, Kleinhappl B, Enzinger C, Stradner MH, Greinix HT, Schlenke P, Steinmetz I. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients. Front Immunol. 2021 Dec 07;12:803742. doi: 10.3389/fimmu.2021.803742. eCollection 2021. PMID: 34950155; PMCID: PMC8688243.
Copy Download .nbib Format: NLM
Therapeutic apheresis in hematopoietic cell transplantation.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Worel N, Leitner G, Wagner A, Greinix HT, Höcker P, Kalhs P.
PMID: 27264917
Turk J Haematol. 2008 Dec 05;25(4):164-71.

With the introduction of hematopoietic stem cell transplant (HSCT), transplant-associated problems like graft-versus-host disease (GVHD) and transplant-associated microangiopathy (TAM) have occurred. In addition, approximately 40% of allogeneic HSCTs are performed across the ABO blood group barrier, bearing the risk...

Cite
Worel N, Leitner G, Wagner A, et al. Therapeutic apheresis in hematopoietic cell transplantation. Turk J Haematol. 2008;25(4):164-71
Worel, N., Leitner, G., Wagner, A., Greinix, H. T., Höcker, P., & Kalhs, P. (2008). Therapeutic apheresis in hematopoietic cell transplantation. Turkish journal of haematology : official journal of Turkish Society of Haematology, 25(4), 164-71.
Worel, Nina, et al. "Therapeutic apheresis in hematopoietic cell transplantation." Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 25,4 (2008): 164-71.
Worel N, Leitner G, Wagner A, Greinix HT, Höcker P, Kalhs P. Therapeutic apheresis in hematopoietic cell transplantation. Turk J Haematol. 2008 Dec 05;25(4):164-71. PMID: 27264917.
Copy Download .nbib Format: NLM
Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia.

EClinicalMedicine

Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix HT, Grath EM, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R.
PMID: 31709412
EClinicalMedicine. 2019 Aug 09;15:33-41. doi: 10.1016/j.eclinm.2019.07.019. eCollection 2019 Oct.

BACKGROUND: The role of conditioning intensity and stem cell source on modifying pre-transplantation risk in allogeneic haematopoietic stem cell transplantation (HSCT) is a matter of debate, but crucial when benchmarking centres.METHODS: This Retrospective, multicenter exploratory-validation analysis of 9103 patients,...

Cite
Gratwohl A, Duarte R, Snowden JA, et al. Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine. 2019;15:33-41doi: 10.1016/j.eclinm.2019.07.019.
Gratwohl, A., Duarte, R., Snowden, J. A., van Biezen, A., Baldomero, H., Apperley, J., Cornelissen, J., Greinix, H. T., Grath, E. M., Mohty, M., Kroeger, N., Nagler, A., Niederwieser, D., Putter, H., Brand, R. (2019). Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine, 1533-41. https://doi.org/10.1016/j.eclinm.2019.07.019
Gratwohl, Alois, et al. "Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia." EClinicalMedicine vol. 15 (2019): 33-41. doi: https://doi.org/10.1016/j.eclinm.2019.07.019
Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix HT, Grath EM, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R. Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine. 2019 Aug 09;15:33-41. doi: 10.1016/j.eclinm.2019.07.019. eCollection 2019 Oct. PMID: 31709412; PMCID: PMC6833359.
Copy Download .nbib Format: NLM
Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.

NPJ vaccines

Harrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle JH, Stiasny K, Greinix H, Rabitsch W, Kalhs P, Ramharter M, Burgmann H, Forstner C.
PMID: 34462440
NPJ Vaccines. 2020 Aug 31;5(1):79. doi: 10.1038/s41541-020-00230-2.

No abstract available.

Cite
Harrison N, Grabmeier-Pfistershammer K, Graf A, et al. Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. NPJ Vaccines. 2020;5(1):79doi: 10.1038/s41541-020-00230-2.
Harrison, N., Grabmeier-Pfistershammer, K., Graf, A., Schwarzinger, I., Aberle, J. H., Stiasny, K., Greinix, H., Rabitsch, W., Kalhs, P., Ramharter, M., Burgmann, H., & Forstner, C. (2020). Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. NPJ vaccines, 5(1), 79. https://doi.org/10.1038/s41541-020-00230-2
Harrison, Nicole, et al. "Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients." NPJ vaccines vol. 5,1 (2020): 79. doi: https://doi.org/10.1038/s41541-020-00230-2
Harrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle JH, Stiasny K, Greinix H, Rabitsch W, Kalhs P, Ramharter M, Burgmann H, Forstner C. Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. NPJ Vaccines. 2020 Aug 31;5(1):79. doi: 10.1038/s41541-020-00230-2. PMID: 34462440.
Copy Download .nbib Format: NLM
Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health.

Bone marrow transplantation

Wolff D, Herzberg PY, Herrmann A, Pavletic SZ, Heussner P, Mumm F, Höfer C, Hilgendorf I, Hemmati PG, Holler E, Greinix H, Mitchell SA.
PMID: 34413472
Bone Marrow Transplant. 2021 Oct;56(10):2618. doi: 10.1038/s41409-021-01404-9.

No abstract available.

Cite
Wolff D, Herzberg PY, Herrmann A, et al. Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone Marrow Transplant. 2021;56(10):2618doi: 10.1038/s41409-021-01404-9.
Wolff, D., Herzberg, P. Y., Herrmann, A., Pavletic, S. Z., Heussner, P., Mumm, F., Höfer, C., Hilgendorf, I., Hemmati, P. G., Holler, E., Greinix, H., & Mitchell, S. A. (2021). Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone marrow transplantation, 56(10), 2618. https://doi.org/10.1038/s41409-021-01404-9
Wolff, Daniel, et al. "Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health." Bone marrow transplantation vol. 56,10 (2021): 2618. doi: https://doi.org/10.1038/s41409-021-01404-9
Wolff D, Herzberg PY, Herrmann A, Pavletic SZ, Heussner P, Mumm F, Höfer C, Hilgendorf I, Hemmati PG, Holler E, Greinix H, Mitchell SA. Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone Marrow Transplant. 2021 Oct;56(10):2618. doi: 10.1038/s41409-021-01404-9. PMID: 34413472; PMCID: PMC8486661.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries